These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39361189)

  • 1. The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men.
    Matti B; Nguyen CH; Lyndon MP; Zargar-Shoshtari K
    World J Urol; 2024 Oct; 42(1):558. PubMed ID: 39361189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand.
    Matti B; Lyndon M; Zargar-Shoshtari K
    BJU Int; 2021 Dec; 128 Suppl 3():11-17. PubMed ID: 32599662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
    Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
    BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
    Cirulli GO; Davis M; Stephens A; Chiarelli G; Finati M; Corsi N; Williams E; Affas R; Sood A; Buffi N; Lughezzani G; Carrieri G; Salonia A; Briganti A; Montorsi F; Rogers C; Abdollah F
    J Urol; 2024 Oct; 212(4):560-570. PubMed ID: 39079152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum prostate-specific antigen levels and public health implications in three New Zealand ethnic groups: European, Maori, and Pacific Island men.
    Gray M; Borman B; Crampton P; Weinstein P; Wright C; Nacey J
    N Z Med J; 2005 Feb; 118(1209):U1295. PubMed ID: 15711628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
    Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
    Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
    Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
    BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand.
    Obertová Z; Scott N; Brown C; Stewart A; Lawrenson R
    BJU Int; 2015 Apr; 115 Suppl 5():24-30. PubMed ID: 25124231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Maori and Pacific Islander men present with more advanced prostate cancer than European New Zealand men? An analysis of 486 men undergoing biopsy in Auckland.
    Pokorny MR; Scott DJ
    BJU Int; 2011 Apr; 107 Suppl 3():27-32. PubMed ID: 21492373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
    Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
    JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Prostate-Specific Antigen Screening on Prostate Cancer Incidence and Mortality in China: 13-Year Prospective Population-Based Cohort Study.
    Ruan X; Zhang N; Wang D; Huang J; Huang J; Huang D; Chun TTS; Ho BSH; Ng AT; Tsu JH; Zhan Y; Na R
    JMIR Public Health Surveill; 2024 Jan; 10():e47161. PubMed ID: 38236627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau).
    Prause LW; Manka L; Millan C; Lang E; Wyler SF; Grobholz R; Hammerer-Lercher A; Sulser T; Recker F; Kwiatkowski M; Eberli D
    World J Urol; 2020 Oct; 38(10):2485-2491. PubMed ID: 31865534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment modalities for Māori and New Zealand European men with localised prostate cancer.
    Obertová Z; Lawrenson R; Scott N; Holmes M; Brown C; Lao C; Tyrie L; Gilling P
    Int J Clin Oncol; 2015 Aug; 20(4):814-20. PubMed ID: 25557325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
    Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
    BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.